فهرست نشریات علمی دسترسی آزاد ایران

Background and objectives: Glucomannan is known for various therapeutic properties, including antidiabetic, anti-obesity, antihyperlipidemic, and anti-inflammatory effects. This study examined the anti-inflammatory mechanism of glucomannan in a carrageenan-induced rat paw edema model and compared its activity with indomethacin. Methods: Thirty male rats were divided into five groups: a carrageenan control group, an indomethacin group (10 mg/kg BW), and three glucomannan groups receiving 100, 200, or 400 mg/kg BW. Treatments were administered orally 30 minutes before carrageenan injection. Paw edema was assessed at baseline and at 1, 3, and 5 hours post-induction. Inflammatory markers were analyzed through immunohistochemistry for NF-κB, ELISA for IL-6 and TNF-α, and colorimetric assays for COX-1 and COX-2 activities. Results: Carrageenan produced a progressive increase in paw volume, while indomethacin markedly suppressed edema formation across all time points. Glucomannan also reduced paw edema in a dose-dependent manner, with the highest dose (400 mg/kg) approaching the efficacy of indomethacin. Biochemical and immunohistochemical analyses demonstrated significant downregulation of NF-κB, IL-6, TNF-α, COX-1, and COX-2 in the indomethacin and glucomannan groups compared with the control (p<0.05). Histopathological evaluation of paw tissues revealed extensive inflammatory cell infiltration, vascular congestion, and tissue edema in the control group, whereas indomethacin and high-dose glucomannan showed markedly reduced. Conclusion: These results suggest that glucomannan exerts anti-inflammatory effects by inhibiting NF-κB activation and suppressing pro-inflammatory cytokines and cyclooxygenase pathways. Its efficacy, particularly at 400 mg/kg, demonstrates promising therapeutic potential comparable to indomethacin, supporting glucomannan as a potential natural anti-inflammatory candidate.